原发性硬化性胆管炎患者的饮酒情况。
Alcohol consumption in patients with primary sclerosing cholangitis.
机构信息
Department of Gastroenterology and Hepatology, Karolinska University Hospital, Karolinska Institutet, 14186 Stockholm, Sweden.
出版信息
World J Gastroenterol. 2012 Jun 28;18(24):3105-11. doi: 10.3748/wjg.v18.i24.3105.
AIM
To assess the alcohol drinking patterns in a cohort of primary sclerosing cholangitis (PSC) patients and the possible influence on the development of fibrosis.
METHODS
Ninety-six patients with PSC were evaluated with a validated questionnaire about a patient's lifetime drinking habits: the lifetime drinking history (LDH) questionnaire. In addition, clinical status, transient elastography and biochemistry values were analysed and registered. Patients were defined as having either significant or non-significant fibrosis. Significant fibrosis was defined as either an elastography value of ≥ 17.3 kPa or the presence of clinical signs of cirrhosis. Patients were divided into two groups depending on their alcohol consumption patterns; no/low alcohol consumption (one drink or unit/d) and moderate/high alcohol consumption (≥ 1 drink or unit/d). LDH data were calculated to estimate lifetime alcohol intake (LAI), current alcohol intake, drinks per year before and after diagnosis of PSC. We also calculated the number of episodes of binge-drinking (defined as consuming ≥ 5 drinks per occasion) in total, before and after the diagnosis of PSC.
RESULTS
The mean LAI was 3882 units of alcohol, giving a mean intake after onset of alcohol consumption of 2.6 units per week. Only 9% of patients consumed alcohol equal to or more than one unit per day. Current alcohol intake in patients with significant fibrosis (n = 26) was less than in patients without significant fibrosis (n = 70), as shown by lower values of phosphatidylethanol (B-PEth) (0.1 μmol/L vs 0.33 μmol/L, respectively, P = 0.002) and carbohydrate-deficient transferrin (CDT) (0.88% vs 1.06%, respectively, P = 0.02). Self-reported LAI was similar between the two groups. Patients with significant fibrosis reduced their alcohol intake after diagnosis from 103 to 88 units per year whereas patients without fibrosis increased their alcohol intake after PSC diagnosis from 111 to 151 units/year. There were no correlations between elastography values and intake of alcohol (units/year) (r = -0.036).
CONCLUSION
PSC patients have low alcohol consumption. The lack of correlation between fibrosis and alcohol intake indicates that a low alcohol intake is safe in these patients.
目的
评估原发性硬化性胆管炎（PSC）患者队列中的饮酒模式，并探讨其对纤维化发展的可能影响。
方法
采用经过验证的终生饮酒习惯问卷（即终生饮酒史问卷）对 96 例 PSC 患者进行评估。此外，还分析和记录了患者的临床状况、瞬时弹性成像和生物化学值。将患者定义为存在显著或非显著纤维化。显著纤维化定义为弹性成像值≥17.3 kPa 或存在肝硬化临床征象。根据饮酒模式将患者分为两组：低/无饮酒（≤1 份/单位/天）和中/高饮酒（≥1 份/单位/天）。计算终生酒精摄入量（LAI）、当前饮酒量、诊断前和诊断后每年的饮酒量来评估 LDH 数据。我们还计算了总的、诊断前和诊断后 binge-drinking 发作次数（定义为每次饮酒≥5 份）。
结果
平均 LAI 为 3882 个酒精单位，意味着开始饮酒后的平均每周摄入量为 2.6 个单位。仅有 9%的患者每天摄入的酒精量等于或超过 1 个单位。26 例存在显著纤维化的患者当前的酒精摄入量低于 70 例无显著纤维化的患者，表现为磷脂酰乙醇（B-PEth）（分别为 0.1 μmol/L 和 0.33 μmol/L，P=0.002）和糖缺失转铁蛋白（CDT）（分别为 0.88%和 1.06%，P=0.02）的水平更低。两组的自我报告 LAI 相似。存在显著纤维化的患者在诊断后每年的酒精摄入量从 103 单位减少到 88 单位，而无纤维化的患者在 PSC 诊断后每年的酒精摄入量从 111 单位增加到 151 单位。弹性成像值与饮酒量（单位/年）之间无相关性（r = -0.036）。
结论
PSC 患者的饮酒量较低。纤维化与饮酒量之间缺乏相关性表明，这些患者低饮酒量是安全的。
Zotero 插件